Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5337 - Prognostics factors in Adenoid Cystic Carcinoma of the Head and Neck (ACCHN): retrospective study of 15 years

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Priscila Nejo

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

P. Nejo1, R.S. Conde1, S. Esteves2, M.T.A. Alexandre1, M. Ferreira1, E. Netto3, J. Santos4, M. Magalhães5, A. Moreira1

Author affiliations

  • 1 Medical Oncology, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., 1099-023 - Lisbon/PT
  • 2 Biostatistics, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., 1099-023 - Lisbon/PT
  • 3 Radiotherapy, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., 1099-023 - Lisbon/PT
  • 4 Head And Neck Surgery, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., 1099-023 - Lisbon/PT
  • 5 Otorhinolaryngology, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., 1099-023 - Lisbon/PT

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5337

Background

ACCHN is a rare entity mainly found in the major and minor salivary glands. Localized disease is frequent and very late recurrences are common. The treatment of choice is surgery, when feasible, followed by radiotherapy (RT). RT alone is used in unresectable [RC1] patients (pts).

Methods

Retrospective analyses of consecutive pts with ACCHN from Jan 2000 to Dec 2015 at Instituto Português de Oncologia de Lisboa was done [RC1]. Aims: to characterize clinical, demographic and treatment data, the related prognostic factors and evaluate the 5-years overall survival (OS) and the disease-free survival (DFS) for non-metastatic pts, and the 5-years OS for the entire cohort.

Results

Of the 112 pts with ACCHN, 100 had localized and 12 metastatic disease. The median age at diagnosis was 62 years (range 18-91). Of the 100 pts with localized disease, the most frequent location was in major salivary glands (40%) followed by minor salivary glands in oral cavity (28%). At presentation, T3/T4 tumors was found in 35% of pts and positive lymph nodes in 5%. Curative surgery was performed in 91% of pts and adjuvant RT in 86%. Positive surgical margins were R1 in 52% of pts and R2 in 15%. Perineural invasion was present in 68%. Of the 100 pts, 32 recurred, 16 locally and 13 of these had a second [RC1] surgery. Palliative cisplatin-based chemotherapy was used 12%. With a median follow-up of 6 years, the disease-free survival at 5 years was 63% (CI 95%, 53-75). The median time to recurrence in relapse pts was 24 months. Positive surgical margin (R1/R2) (p = 0.0045) and T3/T4 tumors (p = 0.000165) significantly reduced DFS and OS. Perineural invasion, positive lymph nodes and radiotherapy treatment did not impact on local control. The 5-years OS for the localized ACCHN was 71% (CI 95%, 62-82) and 68% (CI 95%, 59-78) for the global cohort.

Conclusions

Tumor size and surgical margins were found to be prognostic factors for local control and for survival. The low percentage of positive lymph nodes probably prevents its prognostic value. Our survival data was similar to those found in the literature.

Clinical trial identification

Legal entity responsible for the study

Instituto Português de Oncologia de Lisboa Francisco Gentil.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.